10-Q quarterly report · filed Nov 5, 2026

Viatris (VTRS) Q3 2026 10-Q Quarterly Report

Short answer

Viatris (VTRS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $3.7B (down 0.3% year over year) with net income of −$325M.

Q3 2026 key financials · XBRL

Revenue
$3.7B
−0.3% YoY · −0.3% QoQ
Net income
−$325M
−153.7% YoY · −173.8% QoQ
Operating margin
7.0%
Gross margin
38.5%
EPS (diluted)
−$0.28
−133.3% YoY · −180.0% QoQ

Source: XBRL data from the Viatris (VTRS) Q3 2026 10-Q on SEC EDGAR. USD.

Viatris Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $3.75B vs $3.76B, down $10.4M YoY, essentially flat
  • Gross margin 38% vs 36%; adjusted gross margin approximately 58% vs 56%
  • Best segment Greater China: $702.6M, up 14%; worst Emerging Markets: $529.1M, down 7%
  • Operating cash flow $1.67B through September, up $169.4M; repurchases $150.0M in Q3
  • Nashik disruption: approximately $100M Q4 revenue impact; production expected to resume Q1 2027

Risk Factors

  • New acquisition risk: Pacira transaction may fail or face delays due to tender, regulatory, legal and closing conditions
  • Most material update: Pacira integration may underperform, limiting anticipated benefits, synergies and operating efficiencies
  • Regulatory risk: Hart-Scott-Rodino waiting-period expiration required before Pacira offer completion
  • Operational risk: Viatris may fail to retain Pacira talent supporting commercial, market access, medical affairs and R&D capabilities
  • Financial risk: Transaction setbacks could affect cash flows, dividends, share repurchases and stock price

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Viatris quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.